Screener
Mirum Pharmaceuticals, Inc. MIRM Total Revenue
Total Revenue at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue: | ||||
| Product sales, net | $176,243 | $127,785 | $336,125 | $239,370 |
| Operating expenses: | ||||
| Cost of sales | 30,348 | 23,421 | 59,153 | 46,439 |
| Research and development | 90,528 | 46,067 | 188,438 | 87,111 |
| Acquired in-process research and development | 16,435 | — | 742,737 | 5,000 |
| Selling, general and administrative | 81,469 | 63,286 | 177,799 | 120,992 |
| Total operating expenses | 218,780 | 132,774 | 1,168,127 | 259,542 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s total revenue?
- Mirum Pharmaceuticals, Inc. (MIRM) reported total revenue of $176.24M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s total revenue changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s total revenue increased by 37.9% year-over-year, from $127.79M to $176.24M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s total revenue?
- Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s total revenue has grown at a 128.5% compound annual growth rate (CAGR), from $19.14M to $521.31M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Mirum Pharmaceuticals, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude